Bio Spec Overview
Ignite Creation Date:
2025-12-24 @ 1:18 PM
Last Modification Date:
2025-12-24 @ 1:18 PM
Retention:
SAMPLES_WITH_DNA
Description:
The study will utilize various biological sources to profile RNA for cancer detection and treatment response. Blood samples will be collected from all participants, serving as the source for isolating platelets and immune cells for RNA analysis.
Platelet isolates will be extracted from these blood samples. RNA from platelets will be analyzed to identify transcriptomic profiles that may serve as biomarkers for cancer detection and monitoring. Platelets can absorb RNA from tumor cells, reflecting the cancer's molecular signature.
In Phase 2, immune cell isolates will be separated from the blood samples of cancer patients. RNA from these immune cells will be analysed to assess transcriptomic changes associated with therapeutic responses. Known driver mutations in immune cell DNA will be assessed for correlation with RNA alterations.
This non-invasive approach will leverage liquid biopsy methods to enhance early cancer detection and personalise treatment monitoring.
Platelet isolates will be extracted from these blood samples. RNA from platelets will be analyzed to identify transcriptomic profiles that may serve as biomarkers for cancer detection and monitoring. Platelets can absorb RNA from tumor cells, reflecting the cancer's molecular signature.
In Phase 2, immune cell isolates will be separated from the blood samples of cancer patients. RNA from these immune cells will be analysed to assess transcriptomic changes associated with therapeutic responses. Known driver mutations in immune cell DNA will be assessed for correlation with RNA alterations.
This non-invasive approach will leverage liquid biopsy methods to enhance early cancer detection and personalise treatment monitoring.
Section:
The study will utilize various biological sources to profile RNA for cancer detection and treatment response. Blood samples will be collected from all participants, serving as the source for isolating platelets and immune cells for RNA analysis.
Platelet isolates will be extracted from these blood samples. RNA from platelets will be analyzed to identify transcriptomic profiles that may serve as biomarkers for cancer detection and monitoring. Platelets can absorb RNA from tumor cells, reflecting the cancer's molecular signature.
In Phase 2, immune cell isolates will be separated from the blood samples of cancer patients. RNA from these immune cells will be analysed to assess transcriptomic changes associated with therapeutic responses. Known driver mutations in immune cell DNA will be assessed for correlation with RNA alterations.
This non-invasive approach will leverage liquid biopsy methods to enhance early cancer detection and personalise treatment monitoring.